WHI CV SIG CALL
Wednesday, January 9, 2013
9-10 am PT (noon ET, 11 am CT)
Call number: 1-866-618-2448
Passcode: 9920978
Call Lead By: Marcia Stefanick
Attendees: Tim Assimes, Barbara Howard, Andrew Kaunitz, Liviu Klein, Beth Lewis, Karen Margolis, Lesley
Tinker, Linda VanHorn
AGENDA:
1. May 2-3, 2013 WHI Investigator Meeting (Seattle)
a. Proposal for CV SIG Symposium (as JOINT Symposium with Diabetes/Obesity SIG* and/or Genetics SIG?)
- Marcia sent a draft proposal before the call [*Barbara Howard's presentation)
 Focus on CV Biomarkers, baseline now available for ~10,000 European Ancestry + ~12,000 AA +
Hispanic see: https://cleo.whi.org/data/Pages/GWAS-Data.aspx
 Plan to lay out published papers & approved proposals (to avoid overlap) & stimulate new proposals. Is
there any value proposing new paper now that we have such a big sample even though we have already
written about it?
 Tim Assimes has thought through the genetics part of this and it would be an interesting proposal if
Diabetes/Obesity sig can figure out a way to add this in.
 More discussion of CMS as method for identifying CV outcomes in proposed WHISH (WHI Physical
Activity Trial): composite endpoint including fatal and non-fatal MI, coronary heart disease (CHD)
death, CABG, and stroke
 Comments from CV + HSR SIG members on: fatal and non-fatal MI; CHD death; CABG
 Combining Medical Records Cohort approach with Self-reported Cohort (CMS) approach?
Notes from Joann Manson: For the CV SIG symposium, do you think that a proposal to synthesize what we know
about biomarkers (including genetic markers) and clinical characteristics that facilitate risk stratification for
hormone therapy would be of interest?
The main concept would be that we've learned a lot from WHI about which factors modify risk of CVD, breast
cancer, and other health outcomes on HT. There's increasing evidence that it may be possible to identify women
who are better candidates for HT, i.e., those more likely to have favorable outcomes and less likely to have adverse
events), vs. poorer candidates, by the use of individual risk stratification. Thus, personalized medicine may apply
well to clinical decision-making regarding HT and it may hold promise for improved treatment efficacy and safety.
POSTERS: It is encouraged that Junior & Senior investigators submit abstracts for posters for a $500 award.
TRAVEL: If you are presenting in one of the approved symposia the coordinating center will cover your travel. You
might also want to discuss this with your regional center PIs, who might have travel funds to supplement poster
presenters’ travel.
Discussion of new Paper Proposal Ideas
Updates on any CV findings and new publications?
New Ancillary Study Proposal Ideas
Updates on CV ancillary studies?
Future Calls: NEXT CALL: (9-10am PT (noon ET, 11 am CT) February 13, March 13, April 10, May 8, June 12